Search This Blog

Tuesday, April 1, 2025

Musk derangement syndrome has Dems rejecting everything they claim to stand for

 In this age of rage, it is common for people to become the very thing that they despise in others, jettisoning their most cherished values to strike out at those they hate.

Since the election, Democrats have shown that very self-destructive quality of rage in adopting anti-immigrant, anti-free speech, anti-labor, and even anti-environmental positions to get at Donald Trump or his supporters.

It consumes every part of a person. It is addictive, and it is contagious. What these rage addicts will not admit, however, is that they like it; they need it.

That was evident this week in New York, where democratic legislators are again moving to weaponize state laws for political purposes — just like they did with Trump.

This time, they are targeting Elon Musk, whose dealerships, charging stations, and customers have been hit by political violence from the left.

New York state Sen. Pat Fahy (D-Albany) is pledging to bar Musk from direct sales in the state.

Notably, Fahy has been a longtime advocate of electric vehicles. The move will make it more difficult not just for Musk but other EV dealers to survive, but climate change policies be damned. Fahy and her colleagues want to get at Musk in any way they can.

Fahy explained, “No matter what we do, we’ve got to take this from Elon Musk. He’s part of an effort to go backwards.”

It is hardly the only way Democrats are sacrificing their supposed values to strike at Musk:

* The left decries political violence like January 6th but is largely silent as Teslas are set on fire and Cybertrucks are covered with graffiti. It promote boycotts and rallies with a wink at the vandals. As the violence increases around the country, the left has held protests featuring signs like “Burn a Tesla, Save Democracy.”

* While other billionaires from George Soros to Mark Zuckerberg have spent big on elections for the left, Musk is somehow uniquely evil because he gives money to Republicans. Democrats will defend every illegal immigrant but then meme that a “foreigner” — Musk is a naturalized American — is “meddling” in our government.

* Those who insist that they believe in free speech are supporting censorship and opposing Musk for restoring free speech protections on X.

* In California, labor advocates oppose expanded operations from SpaceX that would benefit workers in the state. California Coastal Commissioner Gretchen Newsom tried to block increased SpaceX launches despite their benefit for both the California economy and national security. No, retaliation for “hopping about the country, spewing and tweeting political falsehoods” was more important.

Still, the greatest hypocrisy may be found in the Democrats’ willingness to abandon environmental priorities for political revenge. It is a contest of virtue-signaling. Fighting for Mother Earth is fine on most days, but nothing compares to destroying Elon Musk.

Lawmakers and advocates are also pressuring pension funds to divest from Tesla while trying to force Tesla showrooms to close — at the cost of New York jobs.

Tesla is an American company making and selling cars in this country. It sells more electric vehicles in the US and New York than any other manufacturer. Yet it must now be destroyed because, unlike a Soros or a Zuckerberg, Musk’s political views are not acceptable to the left.

Tesla was allowed to operate five locations to directly sell to consumers under a 2014 deal because it was viewed as good for New York jobs, the New York economy, and, most importantly, the environment.

None of that matters now.

Fahy explained, “The bottom line is, Tesla has lost their right to promote these when they’re part of an administration that wants to go backwards. Elon Musk was handed a privilege here.”

It also does not matter that companies like Rivian and Lucid (and their employees) will be caught in the crossfire. Nothing matters but revenge.

Many Democrats seem to have lost a capacity for shame. They are disgusted only by the refusal of others to yield to their demands, not the use of any means to achieve political ends. The question is, what do Democrats like Fahy now stand for when everything they are is now defined by those they hate?

Jonathan Turley is the Shapiro professor of public interest law at George Washington University and the author of “The Indispensable Right: Free Speech in an Age of Rage.”

https://nypost.com/2025/04/01/opinion/elon-musk-derangement-syndrome-has-dems-rejecting-everything-they-claim-to-stand-for/

These Ivies are the next targets in Trump’s fight against woke schools

 The Trump administration’s drive to clean up woke elite universities continues, with Princeton and the big tuna, Harvard, both under the microscope. 

Princeton reportedly faces a pause on some $210 million in federal funds as the Department of Education investigates it for allowing antisemitism to fester unchecked, concealed as pro-Palestinian protests. 

Harvard has even bigger financial woes possibly in train, with the feds probing some $8.7 billion in grants and $255 million in contracts with the world’s richest university and premier destination for whiny rich kids, Jew-hating keffiyeh thugs and the rest of the ugly left-wing panoply. 

These are some of the marquee moves in the Trump admin’s 60-school probe. 

And they are beyond necessary. 

Elite schools across America revealed a mile-wide exception for Jews in their purported defense of marginalized and minority groups during the Tentifada that sprang up in support of the monstrous butcheries of Oct. 7. 

But the real problem is far deeper: The Ivies and other top schools abandoned their commitment to actually teaching kids anything long ago. 

And the first Trump term, COVID and the 2020 Floyd riots only served to supercharge their transformation into simply indoctrination centers. 

Even as leaders across top-tier schools were revealed as utter fakes and frauds, like Claudine Gay, Harvard’s former prez and a serial plagiarist.

Or Stanford head Marc Tessier-Lavigne, who quit in 2023 after it was revealed that labs he ran had published fake data, including in papers with his name as principal author. 

These places, in other words, have spent a decade enthusiastically shredding any claim to legitimacy — let alone to taxpayer dollars. 

Now the Trump White House is simply forcing them to follow their own rules.

That’s the real source of all the whining and screaming (well, that and the fact that our professoriate hates America and loves her enemies). 

The only way to end the madness is to hit the schools in their pocketbooks. 

It’s slowly but surely working on Columbia and it’s going to work everywhere else. 

That’s a good thing — as all the panicked squealing proves. 

https://nypost.com/2025/04/01/opinion/why-these-ivies-are-the-next-targets-in-trumps-fight-against-woke-schools/

Booker staffer arrested for carrying gun on Capitol grounds as senator holds floor for over 19 hours

 Capitol Police arrested a staffer for Sen. Cory Booker who was carrying a gun Monday evening, as the New Jersey Democrat kicked off a marathon “filibuster” in the upper chamber.

“Yesterday afternoon a Member of Congress led an IDed staff member around security screening at the Hart Senate Office Building. Later that evening, outside the Senate Galleries, the IDed staff member — who is a retired law enforcement officer — told our officers he was armed,” a rep for US Capitol Police said in a statement Tuesday.

Kevin Batts, a retired Newark Detective and Cory Booker staffer, in an Instagram video, reported to be arrested with a gun at the US Capitol.
Kevin Batts, a retired Newark cop, was arrested for carrying a firearm on Capitol grounds.Instagram/Cory Booker

“The staff member, 59-year-old Kevin A. Batts of New Jersey, was arrested for Carrying a Pistol Without a License. All weapons are prohibited from Capitol Grounds, even if you are a retired law enforcement officer, or have a permit to carry in another state or the District of Columbia.”

Jeff Giertz, a spokesperson for Booker, responded in a statement: “Senator Booker’s office employs a retired Newark police detective as a New Jersey-based driver who often accompanies him to events. We are working to better understand the circumstances around this.”

It’s unclear whether Booker escorted Batts “around security.” In a 2022 Facebook reel, the senator had referred to the staffer as one of his “best” friends.

The former Newark police officer has been a fixture of Booker’s political life since at least 2014, per social media posts, including one in which Booker affectionately calls him “The Batt Man.”

Senator Cory Booker giving a speech on the Senate floor, in a suit and tie, on April 1, 2025
Senator Cory Booker giving a marathon all-night speech on the Senate floor on April 1, 2025AP

“Kevin Batts has been a friend and team member since 2006 when I became [Newark] mayor and even before. I so deeply appreciate his steadfast friendship, incredible dedication to Newark and now his service to the state,” Booker posted on Instagram in January 2016.

“Kevin was raised in Columbus Homes projects in Newark, then spent 6 years in the United States army reserves [sic] and then joined the Newark Police Department and became a detective in 2004. In 2006, he joined my security detail as a member of Newark’s executive protection unit. In 2013 he joined my Senate staff. I am truly blessed by his friendship and loyal hard work.”

Booker bragged shortly after beginning his floor speech at 7 p.m. Monday that he would keep speaking “as long as I am physically able,” and continued to denounce the Trump administration in a rambling address that remains ongoing.

The speech is not technically a talking filibuster, as Booker has not spoken continuously in opposition to a bill or legislative motion.

He’s been speaking for at least 19 hours.

https://nypost.com/2025/04/01/us-news/cory-booker-staffer-arrested-for-carrying-gun-on-capitol-grounds-as-senator-holds-floor-for-more-than-17-hours/

Newsmax stock soars, pushing market cap north of $20 billion after huge IPO success

 Newsmax stock (NMAX) soared as high as 173% Tuesday, extending its massive 735% gain on Monday following the conservative cable news outlet’s IPO.

Newsmax raised $75 million in its IPO Friday, with shares priced at $10. The outlet’s rapid ascent in its first two days of trading pushed its market cap to more than $20 billion Tuesday afternoon, with shares trading as high as $228.

“This incredibly successful offering, combined with our previous Preferred Offering, provides us with the capital and financial freedom to accelerate our growth initiatives, expand our programming, and further enhance our digital presence,” said CEO Christopher Ruddy, a media mogul and friend of President Trump who founded the company in 1998.

https://finance.yahoo.com/news/newsmax-stock-soars-pushing-market-cap-north-of-20-billion-after-shocking-ipo-success-140753184.html

bioAffinity 52-week low, then record revenue

 In a challenging year for bioAffinity Technologies, the company’s stock has plummeted to a 52-week low, trading at just $0.25. According to InvestingPro data, the stock’s RSI indicates oversold conditions, while its beta of 3.14 reflects significant volatility. This significant downturn reflects a staggering 1-year change, with the stock value eroding by -87.89%. Investors have watched with concern as the company struggled to maintain its market position amidst a tough economic landscape, leading to this new low point. With a market capitalization of just $4.08 million and rapid cash burn, the company faces significant challenges. However, analysts forecast 278% revenue growth for the current year. The current price level serves as a stark indicator of the hurdles bioAffinity Technologies has faced over the past year, marking a period of intense volatility and investor caution within the biotech sector. InvestingPro subscribers can access 12 additional key insights about the company’s financial health and future prospects.

In other recent news, bioAffinity Technologies, Inc. reported a notable 270% increase in revenue for the year ended December 31, 2024, reaching $9.4 million, compared to $2.5 million the previous year. This surge is primarily attributed to the increased demand for its CyPath® Lung test, which is now reimbursed by Medicare and private insurers, following its inclusion in the Centers for Medicare and Medicaid Services’ clinical laboratory fee schedule. Despite the revenue growth, the company anticipates a reduction in total revenue for 2025 due to the discontinuation of certain unprofitable services. In a strategic move, bioAffinity has announced cost-saving measures at its subsidiary, Precision Pathology Laboratory Services, aiming for $4 million in annual savings to focus on CyPath® Lung sales. The company also secured a patent in Australia for its lung cancer test, enhancing its intellectual property portfolio. Meanwhile, bioAffinity Technologies faces a potential Nasdaq delisting due to its stock not meeting the minimum bid price requirement, though it has been granted a 180-day period to regain compliance. Additionally, the company’s CEO, Maria Zannes, received a salary increase, reflecting bioAffinity’s recognition of leadership contributions.

https://www.investing.com/news/company-news/bioaffinity-technologies-stock-hits-52week-low-at-025-93CH-3957950

ReShape Lifesciences Inc. (1,900% Jump in Message Volume)

 ReShape Lifesciences saw a surge in retail discussion as traders speculated on the potential approval of its proposed reverse merger with Vyome Therapeutics, first announced in June 2024. 

The metabolic health solutions company stated in January that it was still working with the SEC on its S-4 filing and would set a shareholder meeting date once the filing is declared effective.

Some investor interest also stemmed from reports that Michael Bigger’s fund had taken a significant stake in ReShape. However, sentiment remained mixed after the company raised $6 million through a public offering last month. 

ReShape’s stock is down nearly 80% year-to-date (YTD).

https://www.msn.com/en-in/health/other/reshape-lifesciences-allarity-exact-sciences-cvs-abbvie-5-health-care-stocks-that-led-retail-message-growth-last-week/ar-AA1AAz1J

ACC25: Mineralys' uncontrolled hypertension drug aces trial

 What can you do if a patient with hypertension can't control their blood pressure with the best available drugs? Soon, it may be possible to layer in a therapy from Mineralys Therapeutics – with a new mechanism of action – to help regain control.

That is the conclusion of the Advance-HTN study reported at the American College of Cardiology (ACC) meeting, which found that adding Mineralys' aldosterone synthase inhibitor lorundrostat to the current treatment of uncontrolled hypertension significantly lowered 24-hour blood pressure.

It is thought that around 10% of the 1.3 billion people with hypertension around the world struggle to control their blood pressure using the current main classes of antihypertensive, namely diuretics, calcium channel blockers, and renin-angiotensin system-targeting drugs. That puts them at risk of serious consequences including heart attack, kidney damage, and stroke.

The pivotal study found that lorundrostat lowered 24-hour systolic blood pressure at week 12 by 15.4 mmHg, 7.9 mmHg more than placebo, at a once-daily dose of 50mg. Pushing the dose higher gave no additional treatment benefit but did worsen side effects, which included elevated levels of blood potassium – a side effect that can cause cardiac issues – although all the increases were modest.

"This result was achieved in expertly treated patients who were taking an optimal standardised antihypertensive regimen. In other words, they were patients with uncontrolled and truly treatment-resistant hypertension," said Cleveland Clinic cardiologist Luke Laffin, who presented the data at ACC.

"Additionally, this study's use of 24-hour ambulatory blood pressure monitoring strengthens findings from previous studies of lorundrostat that used office-based monitoring, as ambulatory monitoring is a better predictor of future cardiovascular and kidney risk," he added.

Mineralys now has data from two pivotal trials of lorundrostat, having earlier reported positive results with the drug in the Launch-HTN, which recruited patients in real-world settings rather than the group receiving specialist care in Advance-HTN. It revealed a 19.0 mmHg absolute and 11.7 mmHg placebo-adjusted reduction in blood pressure at week 12.

Prospects for people with uncontrolled hypertension are starting to look up, as various therapies are poised to join decades-old mineralocorticoid receptor blocker spironolactone as treatment options.

Last year, Idorsia Pharma claimed FDA approval for Tryvio (aprocitentan) as the first endothelin receptor antagonist for resistant hypertension, while AstraZeneca has another aldosterone synthase inhibitor, baxdrostat, in phase 3 testing for this indication. AZ acquired baxdrostat when it bought CinCor for $1.3 billion in 2023.

Mineralys' drug is considered to be the furthest along in development in the new class, with others in the pipeline including Damian Pharma's dexfadrostat and Boehringer Ingelheim's vicadrostat (BI 690517).

The company is also running the phase 2 Explore-CKD trial of lorundrostat in chronic kidney disease and is expecting topline data in the coming weeks and recently started another phase 2 trial called Explore-OSA in patients with moderate-to-severe obstructive sleep apnoea (OSA) and hypertension.

https://pharmaphorum.com/news/acc25-mineralys-uncontrolled-hypertension-drug-aces-trial